BioMedNewsBreaks – HippoFi Inc. (ORHB) Collaborates to Deliver One-of-a-Kind Technology Across US Market

HippoFi (OTC: ORHB), a leading health care technology company and authority in spinal biologics, today announced its execution of an exclusive deal with Italian biomedical manufacturing company, BPB Medica. This comes as HippoFi’s PUR Biologics is preparing to launch PURmarrow360 throughout the U.S., aiming to provide a safe and simple surgical device, specifically designed to selectively capture a patient’s own bone marrow aspirate (“BMA”) and mesenchymal stem cells (“MSCs”). Surgeons can combine these patient-specific live-cells with any allograft, allogenic or synthetic bone substitute during surgery. “We are confident in the executive leadership and experience of HippoFi and PUR Biologics and that we have chosen the very best in strategic partners to deliver this unique and one-of-a-kind technology throughout the U.S. market,” said Carlo Bellini, CEO of BPB Medica.

To view the full press release, visit https://ibn.fm/UxVPT

About HippoFi Inc.

HippoFi delivers its cutting-edge health care innovations and propriety technologies through an extensive sales channel network, while implementing first-to-market solutions in the multibillion-dollar biotech, fintech and artificial intelligence (“AI”) markets. HippoFi comprises three segments: regenerative therapeutics, digital payments and AI, and utilizes the same customer channels to commercialize solutions, drive revenue and improve patient outcomes. HippoFi is publicly traded under the symbol ORHB and is headquartered in Irvine, California, USA. For more information, visit www.HippoFi.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork